N- phenylacetyl- 1,3,4,9- tetrahydro- 1H- beta- carboline

an antineoplastic agent that is an antagonist of TGFbeta receptor 1; structure in first source

Also Known As:

YR-290; YR-5510290

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Carbolines: 283
      - N-phenylacetyl-1,3,4,9-tetrahydro-1H-beta-carboline: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Carbolines: 283
        N-phenylacetyl-1,3,4,9-tetrahydro-1H-beta-carboline: 1
  - 3-Ring Heterocyclic Compounds
    - Carbolines: 283
      - N-phenylacetyl-1,3,4,9-tetrahydro-1H-beta-carboline: 1

Experts

1.	Chen, Yihua: 1 article (01/2013)
2.	Fang, Yuanzhang: 1 article (01/2013)
3.	Li, Zhenxi: 1 article (01/2013)
4.	Liu, Mingyao: 1 article (01/2013)
5.	Luo, Jian: 1 article (01/2013)
6.	Qi, Ya: 1 article (01/2013)
7.	Shi, Tieliu: 1 article (01/2013)
8.	Yang, Zhengfeng: 1 article (01/2013)
9.	Yu, Linxi: 1 article (01/2013)
10.	Zhang, Yong: 1 article (01/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/02/2013 - "Treatment with YR-290 also statistically significantly prolonged the survival of tumor-bearing mice. " 01/02/2013 - "Numbers of lung tumor nodules of mice treated with 1mg/kg and 5mg/kg YR-290 were reduced by 74.93% (95% confidence interval = 61.45% to 88.41%) and 94.93% (95% confidence interval = 82.13% to 100%), respectively, compared with control mice. " 01/02/2013 - "YR-290 is a novel inhibitor of tumor metastasis that works by blocking TGFβ signaling pathways." 01/02/2013 - "In tumor metastasis mouse models, YR-290 almost completely blocked cancer metastasis. "
2.	Neoplasm Metastasis (Metastasis) 01/02/2013 - "YR-290 is a novel inhibitor of tumor metastasis that works by blocking TGFβ signaling pathways." 01/02/2013 - "In tumor metastasis mouse models, YR-290 almost completely blocked cancer metastasis. " 01/02/2013 - "YR-290 was also examined for its effects on breast cancer migration, invasion, and metastasis using transwell and epithelial-to-mesenchymal transition (EMT) assays in vitro and three different mouse (BALB/c and NU/NU nude) models (n = 10 per group). " 01/02/2013 - "YR-290 interacted with the kinase domain of TGFβR1, abrogated kinase activity (half maximal inhibitory concentration = 137nM, 95% confidence interval = 126.4 to 147.6nM) and inhibited the TGFβ-mediated downstream signaling pathway and metastasis-associated genes in breast cancer cells. " 01/02/2013 - "Affymetrix GeneChip expression analysis of mRNA levels and real-time polymerase chain reaction were performed to determine expression changes of TGFβ-mediated, metastasis-associated genes in breast cancer cells after treatment with the small-molecule inhibitor YR-290. "
3.	Breast Neoplasms (Breast Cancer) 01/02/2013 - "YR-290 inhibited TGFβ-modulated breast cancer cell migration and invasion. " 01/02/2013 - "YR-290 was also examined for its effects on breast cancer migration, invasion, and metastasis using transwell and epithelial-to-mesenchymal transition (EMT) assays in vitro and three different mouse (BALB/c and NU/NU nude) models (n = 10 per group). " 01/02/2013 - "YR-290 interacted with the kinase domain of TGFβR1, abrogated kinase activity (half maximal inhibitory concentration = 137nM, 95% confidence interval = 126.4 to 147.6nM) and inhibited the TGFβ-mediated downstream signaling pathway and metastasis-associated genes in breast cancer cells. " 01/02/2013 - "Affymetrix GeneChip expression analysis of mRNA levels and real-time polymerase chain reaction were performed to determine expression changes of TGFβ-mediated, metastasis-associated genes in breast cancer cells after treatment with the small-molecule inhibitor YR-290. "

Related Drugs and Biologics

1.	Messenger RNA (mRNA)
2.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)